Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far in an early clinical trial,…
News
Cellcentric has raised $220 million in financing to support two clinical trials testing its potentially first-in-class oral therapy inobrodib in people with hard-to-treat…
A new genetic test for a group of blood cancers known as myeloid malignancies is expected to soon be available to certain people in…
An artificial intelligence (AI) tool can detect early-stage pancreatic cancer on standard medical scans up to three years before a clinical diagnosis, according to…
The first participant has been dosed in a clinical trial testing the experimental therapy GLIX1 in people with recurrent or progressive glioblastoma, an aggressive form…
May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase awareness, support those affected, and…
Gilead said it has completed its $7.8 billion acquisition of Arcellx, a deal the company hopes will allow it to streamline and accelerate the…
The U.S. Food and Drug Administration (FDA) has named Terns Pharmaceuticals’ investigational oral agent TERN-701 a breakthrough therapy for potential use in certain people…
Almost a third of people with advanced pancreatic cancer taking part in an ongoing clinical trial had stable disease following treatment with the experimental…
Advocates across North America are launching a wave of fundraisers and educational campaigns this week as May kicks off Brain Tumor Awareness Month. From high-profile…
